Efficacy of Ibrutinib in the Treatment of First Early Relapses of CLL
CLINICAL LYMPHOMA MYELOMA & LEUKEMIA(2018)
摘要
About 25% of CLL pts have early relapse (within 24 mos) after first line fludarabine and bendamustine-containing immunochemotherapy. Efficacy of ibrutinib in this particular patient population is relatively poorly studied.
更多查看译文
关键词
CLL,ibrutinib,early relapse
AI 理解论文
溯源树
样例
![](https://originalfileserver.aminer.cn/sys/aminer/pubs/mrt_preview.jpeg)
生成溯源树,研究论文发展脉络
Chat Paper
正在生成论文摘要